Current Issue

Research progress on mitochondrial dysfunction in multiple myeloma

FU Min^1,2, WANG Ze-Yuan^1,2, XIANG Ruo-Hong^1,2, XU Hao^1,2, LIU Jing^1,2, XIAO Xiao-Juan^1,2,*

¹School of Life Sciences, Central South University, Changsha 410013, China；²Key Laboratory of Basic and Applied Hematology in Hunan Province, Central South University, Changsha 410013, China

Abstract

Multiple myeloma ranks as the second most prevalent hematological malignancy. It remains incurable and is characterized by frequent drug resistance and disease relapse. Mitochondria, as a key hub for cellular energy metabolism and homeostasis regulation, have been found to have functional abnormalities in various cancers. The occurrence, progression and drug resistance of multiple myeloma are also closely linked to mitochondrial dysfunction. Existing research has shown that multiple myeloma cells acquire survival advantages and escape therapeutic elimination by enhancing oxidative phosphorylation, reprogramming glycolysis, maintaining redox homeostasis, regulating calcium homeostasis and mitochondrial quality control, as well as inhibiting mitochondria-dependent apoptosis. Multiple types of drugs and combination therapy strategies targeting the above processes have shown potential in preclinical studies. This review summarizes the main role of mitochondrial dysfunction in the development and drug resistance of multiple myeloma, as well as the research progress of targeted therapy, providing new ideas for targeted therapy of multiple myeloma.

Key words: multiple myeloma; mitochondrial dysfunction; targeted therapy; drug resistance

Received: 　　Accepted:

Corresponding author: 萧小鹃　　E-mail:

DOI: 10.13294/j.aps.2026.0081

Citing This Article：

FU Min, WANG Ze-Yuan, XIANG Ruo-Hong, XU Hao, LIU Jing, XIAO Xiao-Juan. Research progress on mitochondrial dysfunction in multiple myeloma. Acta Physiol Sin 2026; 78 (4): 851-866 (in Chinese with English abstract).